Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) has announced new equity awards for nine recently hired non-executive employees. The Compensation Committee approved restricted stock awards totaling 27,500 shares of common stock as employment inducements. These awards will vest over three years, with one-third of the shares vesting annually on the grant date anniversary. Full vesting will occur on the third anniversary, contingent on continued employment.
Abeona Therapeutics (Nasdaq: ABEO) ha annunciato nuovi premi azionari per nove dipendenti non esecutivi recentemente assunti. Il Comitato di Compensazione ha approvato premi azionari ristretti per un totale di 27.500 azioni ordinarie come incentivi all'assunzione. Questi premi matureranno nell'arco di tre anni, con un terzo delle azioni che maturerà annualmente nell'anniversario della data di concessione. La maturazione completa avverrà al terzo anniversario, a condizione di un impiego continuativo.
Abeona Therapeutics (Nasdaq: ABEO) ha anunciado nuevos premios de acciones para nueve empleados no ejecutivos recientemente contratados. El Comité de Compensación aprobó premios de acciones restringidas por un total de 27,500 acciones ordinarias como incentivos para el empleo. Estos premios se consolidarán durante tres años, con un tercio de las acciones consolidándose anualmente en el aniversario de la fecha de concesión. La consolidación completa ocurrirá en el tercer aniversario, sujeto a la continuación del empleo.
아베오나 테라퓨틱스 (Nasdaq: ABEO)는 최근에 고용된 비상임 직원 9명에게 새로운 주식 보상을 발표했습니다. 보상위원회는 고용 유인으로 27,500주의 보통 주식에 대한 제약 주식 보상을 승인했습니다. 이 보상은 3년 동안 확정됩니다, 주식의 3분의 1이 부여일 기념일에 매년 확정됩니다. 전체 확정은 고용 지속 조건 하에 3주년 기념일에 발생합니다.
Abeona Therapeutics (Nasdaq: ABEO) a annoncé de nouvelles attributions d’actions pour neuf employés non exécutifs récemment embauchés. Le Comité de Rémunération a approuvé des attributions d'actions restreintes totalisant 27 500 actions ordinaires en tant qu'incitations à l'emploi. Ces attributions s'échelonneront sur trois ans, un tiers des actions étant acquis chaque année à l'anniversaire de la date d'attribution. L'acquisition complète se fera au troisième anniversaire, sous réserve de la poursuite de l'emploi.
Abeona Therapeutics (Nasdaq: ABEO) hat neue Aktienvergütungen für neun kürzlich eingestellte nicht-executive Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte beschränkte Aktienzuteilungen in Höhe von insgesamt 27.500 Aktien des Stammkapitals als Anreiz für die Anstellung. Diese Zuteilungen werden über drei Jahre gesperrt, wobei ein Drittel der Aktien jährlich am Jahrestag des Zuschusses freigegeben wird. Die vollständige Freigabe erfolgt am dritten Jahrestag, vorausgesetzt, die Anstellung wird fortgesetzt.
- Successful recruitment of nine new employees indicating company growth
- Implementation of employee retention strategy through equity-based compensation
- Potential shareholder dilution from issuance of 27,500 new shares
CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On October 31, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to nine individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 27,500 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
How many shares did Abeona Therapeutics (ABEO) grant in its latest employee inducement awards?
What is the vesting schedule for Abeona Therapeutics' (ABEO) October 2024 employee stock awards?
How many new employees received stock grants from Abeona Therapeutics (ABEO) in October 2024?
